Expression Profile of Epithelial Protein Lost in Neoplasm-Alpha (EPLIN-α) in Human Pulmonary Cancer and Its Impact on SKMES-1 Cells in vitro

HTML  Download Download as PDF (Size: 908KB)  PP. 452-459  
DOI: 10.4236/jct.2012.324058    3,631 Downloads   5,973 Views  Citations

ABSTRACT

Epithelial Protein Lost in Neoplasm (EPLIN) is a cytoskeletal associated protein implicated in regulating actin dynamoics and cellular motility and whose expression is frequently downregulated in a number of human cancers. The current study examined the expression levels of EPLIN-α in a pulmonary cancer cohort and its association with clinical pathological factors using quantitative polymerase chain reaction. Additionally, EPLIN-α was over-expressed in the SKMES-1 pulmonary cancer cell line through transfection with a plasmid containing the expression sequence for EPLIN-α. The role of EPLIN-α was subsequently examined using a variety of in vitro functional assays. Decreased levels of EPLIN-α were seen in cancerous tissues compared to normal background tissue. Lower levels of EPLIN-α were also associated with higher TNM stage and nodal involvement. In vitro over-expression of EPLIN-α inhibited SKMES-1 growth rates (p = 0.05 vs. plasmid control) and motility (p = 0.002 vs. plasmid control), though did not have any significant effects on cell-matrix adhesion or cell invasion. Taken together, the current study indicates that lower levels of EPLIN-α may be associated with poorer prognosis and more advanced pulmonary cancer, where this molecule appears to play a suppressive role on cell growth and migration.

Share and Cite:

Y. Liu, A. Sanders, L. Zhang and W. Jiang, "Expression Profile of Epithelial Protein Lost in Neoplasm-Alpha (EPLIN-α) in Human Pulmonary Cancer and Its Impact on SKMES-1 Cells in vitro," Journal of Cancer Therapy, Vol. 3 No. 4A, 2012, pp. 452-459. doi: 10.4236/jct.2012.324058.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.